Fresenius Medical Care AG & Co. (Pref) (FME) Given a €95.60 Price Target by JPMorgan Chase & Co. Analysts

Fresenius Medical Care AG & Co. (Pref) (ETR:FME) received a €95.60 ($113.81) price target from analysts at JPMorgan Chase & Co. in a note issued to investors on Thursday. The brokerage currently has a “buy” rating on the stock. JPMorgan Chase & Co.’s price target would indicate a potential upside of 5.64% from the company’s previous close.

Several other brokerages have also recently weighed in on FME. Nord/LB set a €93.00 ($110.71) target price on shares of Fresenius Medical Care AG & Co. (Pref) and gave the company a “buy” rating in a report on Thursday, November 2nd. Morgan Stanley set a €90.00 ($107.14) target price on shares of Fresenius Medical Care AG & Co. (Pref) and gave the company a “buy” rating in a report on Friday, September 15th. Goldman Sachs Group set a €97.00 ($115.48) target price on shares of Fresenius Medical Care AG & Co. (Pref) and gave the company a “buy” rating in a report on Friday, September 29th. S&P Global set a €95.00 ($113.10) target price on shares of Fresenius Medical Care AG & Co. (Pref) and gave the company a “buy” rating in a report on Monday, November 6th. Finally, Berenberg Bank set a €95.60 ($113.81) target price on shares of Fresenius Medical Care AG & Co. (Pref) and gave the company a “buy” rating in a report on Tuesday, October 24th. Ten equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average target price of €90.17 ($107.34).

Shares of Fresenius Medical Care AG & Co. (FME) opened at €90.50 ($107.74) on Thursday. The firm has a market cap of $27,880.00 and a P/E ratio of 22.18. Fresenius Medical Care AG & Co. has a 1-year low of €73.87 ($87.94) and a 1-year high of €90.50 ($107.74).

COPYRIGHT VIOLATION NOTICE: “Fresenius Medical Care AG & Co. (Pref) (FME) Given a €95.60 Price Target by JPMorgan Chase & Co. Analysts” was originally reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The correct version of this piece of content can be viewed at https://www.chaffeybreeze.com/2018/01/06/fresenius-medical-care-ag-95-60-price-target-by-jpmorgan-chase-co-analysts.html.

About Fresenius Medical Care AG & Co. (Pref)

Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services. It offers dialysis treatment, and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized ESRD patients and for patients suffering from acute kidney failure.

Analyst Recommendations for Fresenius Medical Care AG & Co. (Pref) (ETR:FME)

Receive News & Ratings for Fresenius Medical Care AG & Co. (Pref) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. (Pref) and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply